NIH Cuts Research Funding Of Scientist Under Investigation For Cell Paper Data

WASHINGTON -- The National Institutes of Health has begun to withdraw its financial ties to Thereza Imanishi-Kari, the Tufts University immunologist accused of failing to support data in a 1986 Cell paper on gene expression. The decision parallels a new NIH investigation into the case that agency officials say has produced "mounting evidence of inconsistencies" in her work. The latest chapter in the controversy, involving a paper whose coauthors include Nobel laureate David Baltimore, unfolded

Written byJeffrey Mervis
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

WASHINGTON -- The National Institutes of Health has begun to withdraw its financial ties to Thereza Imanishi-Kari, the Tufts University immunologist accused of failing to support data in a 1986 Cell paper on gene expression. The decision parallels a new NIH investigation into the case that agency officials say has produced "mounting evidence of inconsistencies" in her work.

The latest chapter in the controversy, involving a paper whose coauthors include Nobel laureate David Baltimore, unfolded last month during a hearing before a House subcommittee chaired by Rep. John Dingell (D-Mich.). At issue in this third hearing in three years before the subcommittee was the validity of tapes from gamma ray counters in Imanishi-Kari's laboratory that generated data used in the experiments with transgenic mice.

Two Secret Service forensic scientists told the oversight and investigations subcommittee of the House Energy and Commerce Committee that their analysis of the material suggests that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies